Roche Exits Semiconductor, Nanopore Sequencing; Cuts 60 Positions at 454 as It Builds New NGS Unit | GenomeWeb

Roche is shutting down its research and development efforts in semiconductor sequencing and nanopore sequencing and is consolidating its 454 and NimbleGen products into a new sequencing unit that will cover both life science and clinical diagnostic applications.

The changes are part of the company's decision, announced today, to dissolve Roche Applied Science, the life science unit of its Diagnostics division, by the end of this year and to integrate Applied Science's products with other units.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.